EGFR and non-small cell lung carcinoma: Resistance mutations [8,9], such as the T790M missense mutation in exon 20 of EGFR, play an important role in developing resistance to EGFR inhibitors, forcing researchers to focus on compounds that can overcome this resistance in NSCLC [10,11].